Thursday, Silo Pharma Inc (NASDAQ: SILO) provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD). In November, Silo Pharma announced a new exclusive license agreement with Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for Silo's intranasal therapeutic drug SPC-15. The study aims to identify the maximum tolerated intranasal dose of th
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Successfully Completes First Phase of Dose-Ranging SPC-15 Study streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Silo Pharma, Inc. (NASDAQ:SILO – Get Free Report) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totalling 55,800 shares, a drop of 28.7% from the November 30th total of 78,300 shares. Approximately 2.2% of the shares of the stock are sold short. Based […]
Silo Pharma (SILO) and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Silo dosage and time-release formulation aim for potential first at-home Ketamine therapeutic SARASOTA, FL, Dec. 28, 2023 Silo Pharma, Inc. , a developmental stage biopharmaceutical.